Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF Vaccine Phase 3 Study in Japanese Adults
NCT05242432Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Neutralizing Antibody Titers Against RSV A Strain at Day 15 and Occurrence of RT-PCR Confirmed RSV-mediated Lower Respiratory Tract Disease up to 11.5 months. Started Apr 2022; status: terminated.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05242432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242432.